SAB Biotherapeutics Inc (SABS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
SAB Biotherapeutics Inc stock (SABS) is currently trading at $3.82. SAB Biotherapeutics Inc PS ratio (Price-to-Sales) is 1593.84. Analyst consensus price target for SABS is $9.50. WallStSmart rates SABS as Sell.
- SABS PE ratio analysis and historical PE chart
- SABS PS ratio (Price-to-Sales) history and trend
- SABS intrinsic value — DCF, Graham Number, EPV models
- SABS stock price prediction 2025 2026 2027 2028 2029 2030
- SABS fair value vs current price
- SABS insider transactions and insider buying
- Is SABS undervalued or overvalued?
- SAB Biotherapeutics Inc financial analysis — revenue, earnings, cash flow
- SABS Piotroski F-Score and Altman Z-Score
- SABS analyst price target and Smart Rating
SAB Biotherapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
SAB Biotherapeutics Inc (SABS) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and price/sales. Significant fundamental concerns warrant caution or avoidance.
SAB Biotherapeutics Inc (SABS) Key Strengths (3)
Trading at 1.82x book value, attractively priced
58.77% held by institutions, strong professional interest
Solid profitability: $15 profit per $100 equity
Supporting Valuation Data
SAB Biotherapeutics Inc (SABS) Areas to Watch (4)
Revenue declining -62.40%, a shrinking business
Earnings declining -60.00%, profits shrinking
Very expensive at 1593.8x annual revenue
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
SAB Biotherapeutics Inc (SABS) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 3 register as strengths (avg 7.7/10) while 4 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own., Return on Equity. Valuation metrics including Price/Book (1.82) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 15.00%.
The Bear Case
The primary concerns are Revenue Growth, EPS Growth, Price/Sales. Some valuation metrics including Price/Sales (1593.84) suggest expensive pricing. Growth concerns include Revenue Growth at -62.40%, EPS Growth at -60.00%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 15.00% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -62.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Revenue Growth and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SABS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SABS's Price-to-Sales ratio of 1593.84x sits near its historical average of 1611.63x (14th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 6% below its historical high of 1701.76x set in Mar 2026, and 1% above its historical low of 1573.09x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for SAB Biotherapeutics Inc (SABS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
SAB Biotherapeutics Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 114,700 with 62% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
ROE of 1500.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Spending 9353% of revenue (11M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 62% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -18M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact SAB Biotherapeutics Inc.
Bottom Line
SAB Biotherapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About SAB Biotherapeutics Inc(SABS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. The company is headquartered in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.